Breaking news

Cyprus Sets Cap On Third-Country Students In Private Higher Education Institutions

by THEFUTURE.TEAM

July 25, 2024

In a significant policy shift, the Cypriot government has implemented a cap on the number of students from non-EU countries enrolled in private higher education institutions. This new regulation, ratified by the Cabinet, aims to strike a balance between attracting international talent and maintaining educational standards while ensuring adherence to national immigration policies. Effective from the academic year 2024-2025, the cap targets private institutions with high international-student ratios, reflecting Cyprus’ commitment to sustainable growth and quality education.

Rationale Behind the Cap

The decision to introduce this cap is multifaceted. Primarily, it aims to regulate the burgeoning number of international students to ensure that educational quality is not compromised. With a surge in third-country nationals seeking education in Cyprus, there has been growing concern about the capacity of private institutions to maintain high academic standards while accommodating an increasing number of students.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Furthermore, this policy addresses immigration control, ensuring that the influx of students aligns with the country’s broader immigration and demographic strategies. By managing the number of international students, the government aims to streamline the integration process and avoid potential socio-economic imbalances.

Implementation and Impact

The cap will be enforced starting from the 2024-2025 academic year, giving institutions time to adjust their admission processes and align with the new regulations. The Ministry of Education, Sports, and Youth, in collaboration with the Ministry of Interior, will oversee the implementation, ensuring compliance and providing support to institutions during the transition period.

Institutions with a high proportion of third-country students will need to reassess their recruitment strategies and may need to diversify their student base. This shift could lead to enhanced collaboration with EU countries and increased efforts to attract students from within the European Union.

Broader Implications for the Education Sector

This policy is expected to have several implications for the Cypriot education sector. For one, it may prompt private institutions to invest more in facilities, faculty, and resources to attract a diverse student body and maintain competitive standards. Additionally, the cap could encourage a more balanced distribution of international students across various institutions, promoting healthy competition and innovation in the education sector.

Moreover, the cap is part of Cyprus’s broader strategy to enhance the quality of higher education, making it a more attractive destination for high-calibre students globally. By ensuring that private institutions can offer top-notch education without being overwhelmed by numbers, Cyprus aims to solidify its reputation as a hub for quality higher education.

The Future Forbes Realty Global Properties

MammoCheck Secures A €500,000 SEED Grant From The RIF To Advance Toward FDA 510(k) Clearance And EU MDR CE Marking

by News Editor

August 4, 2026

The project is co-funded by the European Union and the Republic of Cyprus under the Cohesion Policy Programme THALIA 2021–2027. Frederick Research Center is participating as a partner organisation, continuing the company’s roots as a spin-out of Frederick University.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

NICOSIA, CYPRUS, July 31, 2026. MammoCheck Ltd, a Cyprus-based medical technology company founded as a spin-out of Frederick University, has secured a €500,000 grant under the Research and Innovation Foundation’s (RIF) SEED programme.

The competitive grant will support the continued development of the company’s adjunctive, research-validated software platform, which combines thermal imaging with artificial intelligence to support breast cancer screening. More specifically, the funding will support the clinical, quality management and regulatory work required as the company advances toward FDA 510(k) clearance in the United States and CE marking under the EU Medical Device Regulation (MDR 2017/745).

The RIF’s SEED programme supports innovative Cypriot start-ups developing internationally competitive products and services. It is co-funded by the European Union through the European Regional Development Fund and the Republic of Cyprus under the Cohesion Policy Programme THALIA 2021–2027.

For MammoCheck, the funding will support completion of its clinical programme, further development of its quality management system in line with ISO 13485, and preparation of the technical documentation and submissions required for the FDA and EU MDR regulatory pathways.

About MammoCheck

MammoCheck is developing a Software as a Medical Device (SaMD) platform that combines a smartphone application, thermal imaging and a proprietary artificial intelligence algorithm to support breast cancer screening.

Founded in 2024 as a spin-out of Frederick University, the company aims to address unequal access to screening. Mammography coverage remains highly uneven worldwide and has been reported as low as 1.7% in some countries, including among many women under the age of 45 who fall outside most national screening programmes.

The platform is being developed for use in primary care and gynaecology settings, as well as for guided home use, with every result reviewed by a clinician. It is intended to complement, rather than replace, established imaging modalities such as mammography and ultrasound.

MammoCheck is currently conducting a clinical study across hospital sites in Cyprus, approved by the Cyprus National Bioethics Committee.

The Role Of Frederick University

Frederick University continues to support the initiative as the institution from which MammoCheck originated. The collaboration also continues through the participation of the Frederick Research Center as a partner organisation in the funded project.

The centre contributes specialised expertise and infrastructure through its Nursing Department and the Mobile Devices Laboratory, focusing on artificial intelligence, smart systems and scientific dissemination. The collaboration strengthens the connection between Cypriot academic research and internationally oriented innovation.

The Frederick team supporting the project includes Dr. Andreas Constantinides, Associate Professor and Director of the Mobile Devices Laboratory, Dr. Evanthia Asimakopoulou, Assistant Professor in the Nursing Department, and Dr. Elena Papoui, Visiting Lecturer in the Nursing Department.

What The Grant Means

The award adds to a period of continued momentum for the company. Alongside its clinical and regulatory progress, MammoCheck is conducting a private investment round to accelerate commercial deployment as it advances toward key regulatory milestones.

The company also holds a Certificate of Innovative Enterprise from the Cyprus Deputy Ministry of Research, Innovation and Digital Policy, allowing eligible investors participating in the funding round to benefit from tax incentives under Cyprus’ innovation investment legislation.

Statements

“Securing €500,000 in competitive, non-dilutive funding is a strong vote of confidence in our vision, our team and our mission. It allows us to focus on what truly matters right now, turning that vision into reality, step by step, as we move steadily toward FDA 510(k) clearance and CE marking under the EU MDR,” said Alexandra Dimitriadou, Co-Founder and CEO of MammoCheck.

Athina Grigoriou, Co-Founder and CRO, added: “Our clinical programme is at the heart of this project. This support strengthens the study we are conducting across hospital sites in Cyprus and the evidence base behind every step of our regulatory pathway.”

Marios Pafitis, Co-Founder and CTO, said: “Working alongside the Frederick Research Center brings academic rigour to our engineering. This grant helps us take the technology from promising research toward a rigorously engineered and clinically validated product.”

The MammoCheck co-founding team, Alexandra Dimitriadou, Marios Pafitis and Athina Grigoriou, was named to the Forbes 30 Under 30 Greece list in 2026.

The MAMMOCHECK project (SEED/0525(B)/0102) is implemented under the Cohesion Policy Programme THALIA 2021–2027 and is co-funded by the European Union through the European Regional Development Fund and the Republic of Cyprus via the Research and Innovation Foundation.